


# Current and Future Programs Summary



# Filgotinib Marks Expansion into Inflammation with Potential for 5 Launches in Next 4 Years

Inflammation

## Filgotinib


Selective JAK-1 inhibitor with **potential best-in-class profile**

**Strong efficacy for remission and demonstrated safety**  
at both doses; favorable benefit/risk profile at high dose

**Submitted for RA** in U.S., Europe and Japan



**COVID-19 Insight:** Filgotinib for RA filed with regulators globally, including U.S., Europe and Japan. We are continuing to prepare for launch and are in close contact with regulators to understand the effect that COVID-19 could have on review timelines.



**Preparing for competitive RA launch** with highly experienced team



# Building a Broad Inflammation and Fibrosis Portfolio with Galapagos Beyond Filgotinib


Inflammation




Doubles Gilead's R&D footprint and accelerates transformational therapy development

9 clinical programs<sup>1,2</sup>

>20 pre-clinical programs<sup>2</sup>



Selected programs



Lighter shade - new or progressed to next phase since Q4'19

<sup>1</sup> Excluding filgotinib. <sup>2</sup> Optionable partner programs, except for GLPG-1690 which is an optioned partner program. <sup>3</sup> Autotaxin inhibitor. <sup>4</sup> GPR84 antagonist. <sup>5</sup> Toledo - dual mechanism anti-inflammatory. IPF - Idiopathic Pulmonary Fibrosis. OA - Osteoarthritis. Selected pre-clinical and P1 assets displayed.



# Anticipated Milestones Through 2021

